This is because the medicine is still being tested
Before switching or starting either medication, talk to your doctor
In her HBO documentary, Being Serena, one scene shows her coach talking with her about the need for her to lose weight
SGLT2 inhibitors are preferred in people with HF or at high-risk for HF, whereas GLP-1 receptor agonists are favored for those requiring significant weight loss, ASCVD risk reduction, CKD management, or in whom mitigation of metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis is a clinical priority [84]
No more 'just a little something' that accidentally turns into a full second meal
Overall, indirect comparisons suggest that SGLT2 inhibitors may offer greater preservation of eGFR than GLP-1 receptor agonists in a broader population of people with type 2 diabetes mellitus and CKD